<SUBMISSION>
<ACCESSION-NUMBER>0001144204-06-042285
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20061011
<ITEMS>1.01
<ITEMS>2.01
<ITEMS>5.03
<ITEMS>9.01
<FILING-DATE>20061016
<DATE-OF-FILING-DATE-CHANGE>20061013
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED BIOTHERAPY INC
<CIK>0000791833
<ASSIGNED-SIC>8731
<IRS-NUMBER>510402415
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1006
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26323
<FILM-NUMBER>061145039
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
<PHONE>818-8833956
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED BIOTHERAPY CONCEPTS INC
<DATE-CHANGED>19990524
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v054854_8k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      DC 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>FORM
      8-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CURRENT
      REPORT</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Section 13 or 15(d) of the Securities Exchange Act of
      1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date
      of
      Report (Date of earliest event reported) </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>October
      11, 2006</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Advanced
      Biotherapy, Inc. </u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact
      name of registrant as specified in its chapter)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="31%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Delaware</u></font></div>
            </td>
            <td width="4%">&#160; </td>
            <td align="left" valign="top" width="30%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>0-26323</u></font></div>
            </td>
            <td width="4%">&#160; </td>
            <td align="left" valign="top" width="31%" style="border-bottom: medium none;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>51-0402415</u></font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="31%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(State
                or other jurisdiction of</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">incorporation)</font></div>
            </td>
            <td width="4%">&#160;</td>
            <td align="left" valign="top" width="30%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Commission</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">File
                Number)</font></div>
            </td>
            <td width="4%">&#160;</td>
            <td align="left" valign="top" width="31%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(IRS
                Employer</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Identification
                No.)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="50%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">141
                West Jackson Boulevard, Suite 2182 </font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Chicago,
                Illinois</u></font></div>
            </td>
            <td valign="bottom" width="50%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font size="2"><u>60604</u></font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td width="50%">
              <div><font size="2">(Address of principal executive </font></div>
              <div><font size="2">offices)</font></div>
            </td>
            <td valign="top" width="50%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font size="2">(Zip
                Code)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Registrant&#8217;s
      telephone number, including area code </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>(312)
      427-1912</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">Page
          1 of
          4</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
      1.01.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Unregistered
      Sales of Equity Securities</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      August
      28, 2006, the Registrant (or &#8220;Company&#8221;) and Richard P. Kiphart (&#8220;Noteholder&#8221;), a
      director of the Company, entered into a Share Purchase and Debt Restructure
      Agreement (&#8220;Agreement&#8221;). Subject to the terms and conditions of the Agreement,
      the Company agreed to sell an aggregate of 433,333,333 shares (&#8220;New Shares&#8221;) of
      Company common stock, $0.001 par value, at $0.015 per share to the Noteholder,
      certain family members of the Noteholder, Christopher Capps (the Company&#8217;s new
      President and Chief Executive Officer) and other prospective board members,
      for
      the aggregate sum of $6,500,000 (&#8220;New Capital&#8221;). The Company received $1.1
      million of the New Capital from the Noteholder as of August 28, 2006, for which
      the Noteholder acquired 73,333,333 shares of Company common stock. The other
      holders (&#8220;Other Holders&#8221;) of Company convertible notes, promissory notes and
      certain other indebtedness owed by the Company converted the entire principal
      amount thereof, together with accrued interest thereon, into approximately
      35,319,059&#160;shares of Company common stock, at the price of $0.015 per
      share, effective as August 28, 2006, (except for holders of approximately
      $15,460 in Company convertible notes which were paid off by the Company, and
      except for&#160;two other holders of Company convertible notes who
      converted&#160;their notes as described below). On October 6, 2006, the Company
      filed an amendment to its Certificate of Incorporation (&#8220;Amendment to
      Certificate&#8221;) that increased the number of authorized shares of Company common
      stock from 200,000,000 to 2,000,000,000 shares of common stock. As a result
      of
      the filing of the Amendment to Certificate, the balance of the New Capital
      was
      paid to the Company on October 11, 2006, for which the investors acquired
      360,000,000 shares of Company common stock. As of October 11, 2006, the
      Noteholder converted all of his Company convertible notes and other promissory
      notes into approximately 360,988,600 shares of common Company stock, at the
      same
      $0.015 per share conversion price. Also, as of October 11, 2006,&#160;two
      other&#160;holders of Company convertible notes converted all&#160;their Company
      convertible notes into approximately 62,572,467 shares of Company common stock,
      at the same $0.015 per share conversion price. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      new
      shares of Company common stock (&#8220;New Shares&#8221;) issued for the New Capital were
      sold pursuant to the exceptions provided by Section 4(2) of the Securities
      Act
      of 1933, as amended (&#8220;Act&#8221;) and Regulation D, promulgated thereunder. The
      Noteholder and the other persons who acquired New Shares are each an
&#8220;accredited&#8221; investor, as that term is defined in Rule 501 in Regulation D of
      the Act. No general solicitation or advertising was employed by the Company,
      or
      anyone else associated with the Company in connection with the placement of
      the
      New Shares. No commissions were paid. The certificates representing the New
      Shares will bear appropriate restrictive legends. All of the shares being
      acquired by the Noteholder and other holders of Company indebtedness pursuant
      to
      conversion or other exchange of Company debt are being issued pursuant to an
      exemption under the Act and applicable securities laws. All certificates
      representing the shares of Company common stock to be issued to Noteholder
      and
      Other Holders will bear appropriate restrictive legends. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">According
      to the Noteholder, the Noteholder and the other purchasers of New Shares used
      personal funds to acquire the New Shares.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company granted stock options to members of the Board of Directors (except
      Richard P. Kiphart) and members of its Advisory Board to purchase an aggregate
      7,210,000 shares, at an exercise price of $0.03 per share, as of August 28,
      2006.</font></div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
      2.01.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Changes
      in Control of Registrant</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      </font></div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Noteholder acquired from the Company shares of Company common stock constituting
      a majority of the issued and outstanding shares of Company common stock, which
      resulted in a change in control with respect to the stock ownership of the
      Company such that the Noteholder holds the majority of the issued and
      outstanding of the Company common stock. As a result of his share ownership,
      the
      Noteholder is able to elect all of the directors who comprise the Board of
      Directors, which represents a change in the majority control of the Board.
      Pursuant to the Agreement and as of October 11, 2006, the Noteholder acquired
      approximately 83% of the issued and outstanding shares of the Company after
      taking into account the New Capital and conversion of all Company convertible
      notes, promissory notes, and certain other Company indebtedness into shares
      of
      Company common stock.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">Page
          2 of
          4</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
      5.03&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Amendments
      to Articles of Incorporation or Bylaws; Changes in Fiscal Year</u>.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company filed the Amendment to Certificate on October 6, 2006. The Amendment
      to
      Certificate increased the number of authorized shares of Company capital stock
      from 220,000,000 to 2,020,000,000 shares, consisting of 2,000,000,000 shares
      of
      common stock, $.001 par value a share, and 20,000,000 shares of preferred stock,
      $.001 par value per share.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FORWARD-LOOKING
      STATEMENTS</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      Form
      8-K and other reports we file with the Securities and Exchange Commission
      (&#8220;SEC&#8221;) contain forward-looking statements relating to, among other things, the
      Transaction, and our future performance, our business, and future events. All
      statements other than statements of historical facts are forward-looking
      statements, including, without limitation, any statements regarding future
      performance. Some of these forward-looking statements may be identified by
      the
      use of words in the statements such as "anticipate," "estimate," &#8220;could&#8221;
"expect," "project," "intend," "plan," "believe,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;may,&#8221;
&#8220;assume,&#8221; &#8220;continue,&#8221; variations of such words and similar expressions. These
      statements are not guarantees of future performance and involve certain risks,
      uncertainties, and assumptions that are difficult to predict. We caution you
      that our performance and results could differ materially from what is expressed,
      implied, or forecast by our forward-looking statements. Future operating results
      and the Company&#8217;s stock price may be affected by a number of factors, including,
      without limitation: (i) availability of capital; (ii) opportunities for joint
      ventures and corporate partnering; (iii) opportunities for mergers and
      acquisitions to acquire non-biotechnology revenue generating businesses, or
      to
      expand the Company&#8217;s biotechnology base; (iv) regulatory approvals of
      preclinical and clinical trials; (v) intellectual property matters (patents);
      and (vi) competition. Factors that could cause or contribute to such differences
      include, but are not limited to, those discussed in the section entitled &#8220;Item
      1. Business,&#8221; and all subsections therein, including, without limitation, the
      subsections entitled, Technical Background, Government Regulation, Federal
      Drug
      Administration Regulation, Competition, and Factors That May Affect the Company,
      and the section entitled &#8220;Market for Registrant's Common Stock and Related
      Stockholder Matters,&#8221; all contained in the Company&#8217;s Annual Report on Form
      10-KSB for the fiscal year ended December 31, 2005. Given these risks and
      uncertainties, any or all of these forward-looking statements may prove to
      be
      incorrect. Therefore, you should not rely on any such forward-looking
      statements. Except as required under federal securities laws and the rules
      and
      regulations of the SEC, we do not intend to update publicly any forward-looking
      statements to reflect actual results or changes in other factors affecting
      such
      forward-looking statements.</font></div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Item
      9.01.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><u>FINANCIAL STATEMENTS
      AND
      EXHIBITS</u>.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Exhibits</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="50%"><font size="2">Designation</font></td>
            <td width="50%"><font size="2">Description of Exhibit</font></td>
          </tr>
          <tr bgcolor="white">
            <td width="50%">&#160;</td>
            <td width="50%">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td width="50%"><font size="2">3.4</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>1</sup></font></td>
            <td width="50%"><font size="2">Amendment to Certificate of
              Incorporation</font></td>
          </tr>
          <tr bgcolor="white">
            <td width="50%">&#160;</td>
            <td width="50%">&#160;</td>
          </tr>
          <tr bgcolor="white">
            <td width="50%"><font size="2">99.1</font></td>
            <td width="50%"><font size="2">Press Release dated October 13,
              2006</font></td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><br>
      <hr style="COLOR: black" align="left" size="1" width="20%">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div>
        <div>
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>1</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            The
            Registrant intends to correct certain other Exhibit numbers in a subsequent
            filing.</font></div>
        </div>
      </div>
      <div><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">Page
          3 of
          4</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LET
: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Signatures</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant
      has
      duly caused this report to be signed on its behalf by the undersigned hereunto
      duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ADVANCED
                BIOTHERAPY, INC.</strong></font></div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant)</font></div>
              </div>
            </td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:<font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt" size="3">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">October
              13, 2006</font></font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td>&#160;</td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="1" width="74%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Christopher
                W. Capps, President </font></div>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and
                  Chief Executive Officer</font></div>
              </div>
            </td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td>&#160;</td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: -252pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">INDEX
      TO
      EXHIBITS</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div align="center">
        <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="white">
              <td width="50%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Exhibit</u></font></div>
              </td>
              <td width="50%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Description</u></font></div>
              </td>
            </tr>
            <tr bgcolor="white">
              <td width="50%">&#160;</td>
              <td width="50%">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td width="50%"><font size="2">3.4</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"><sup>1</sup></font></td>
              <td width="50%"><font size="2">Amendment to Certificate of
                Incorporation</font></td>
            </tr>
            <tr bgcolor="white">
              <td width="50%">&#160;</td>
              <td width="50%">&#160;</td>
            </tr>
            <tr bgcolor="white">
              <td width="50%"><font size="2">99.1</font></td>
              <td width="50%"><font size="2">Press Release dated October 13,
                2006</font></td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <hr style="COLOR: black" align="left" size="1" width="20%">
      <div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>1</sup>&#160;The
          Registrant intends to correct certain other Exhibit numbers in a subsequent
          filing.</font></div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 252pt; TEXT-INDENT: -252pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">Page
          4 of
          4</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v054854_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT
      99.1</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td valign="top" width="30%"><img src="logo.jpg" alt=""></td>
            <td valign="top" width="29%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font size="6">A</font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">DVANCED</font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 20pt; FONT-FAMILY: Times New Roman">B</font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">IOTHERAPY</font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">,</font><font style="DISPLAY: inline; FONT-SIZE: 20pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 20pt; FONT-FAMILY: Times New Roman">I</font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">NC</font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">.</font></div>
            </td>
            <td width="41%">&#160;</td>
          </tr>

      </table>
    </div>
    <div>
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td valign="top" width="59%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
            </td>
            <td width="1%" bgcolor="black">&#160;</td>
            <td width="40%">
              <div>&#160;</div>
              <div>
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u><strong>Administration</strong></u></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>c/o
                  KVG Partners</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>141
                  West Jackson Blvd., Suite 2182</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Chicago,
                  Illinois 60604</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Telephone
                  312-427-1912</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Fax
                  312-427-5396</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>www.advancedbiotherapy.com</strong></font></div>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: -36pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">October
      13, 2006</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#8220;FOR
      IMMEDIATE RELEASE&#8221;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Advanced
      Biotherapy, Inc. Completes Stock Sale and Debt
      Conversion</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Advanced
      Biotherapy, Inc. announced today that it has completed the sale of common stock
      to Richard P. Kiphart and other new investors in the amount of $5.4 million.
      This investment, plus the previous $1.1 million invested by Richard P. Kiphart
      around August 28, 2006, completes the $6.5 million capital raise previously
      announced by the Company. The Company also announced the conversion of all
      convertible notes, other promissory notes and accrued salaries owed by the
      Company, except for a nominal amount which was paid out in cash. The Company
      has
      no long-term debt and has approximately $6.2 million in cash, as of October
      12,
      2006.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>About
      Advanced Biotherapy</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company, a pioneer in anticytokine therapy, has demonstrated the effectiveness
      of its pioneering scientific strategy by conducting investigational clinical
      trials treating patients suffering from AIDS, multiple sclerosis, rheumatoid
      arthritis, corneal transplant rejection and certain autoimmune skin conditions,
      including alopecia, all Th1 mediated autoimmune diseases which appear to have
      the same proinflammatory Th-1 activity. Advanced Biotherapy is headquartered
      in
      Chicago with laboratories in Columbia, Maryland. The company has an extensive
      patent portfolio including 7 issued patents. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Forward-Looking
      Statements </u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Statements
      made in this news release, other than statements of historical fact, are
      forward-looking statements and are subject to a number of uncertainties that
      could cause actual results to differ materially from the anticipated results
      or
      other expectations expressed in our forward-looking statements.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Some of
      these forward-looking statements may be identified by the use of words in the
      statements such as "anticipate," "estimate," &#8220;could&#8221; "expect," "project,"
      "intend," "plan," "believe,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; &#8220;assume,&#8221; &#8220;continue,&#8221;
variations of such words and similar expressions. These statements are not
      guarantees of future performance and involve certain risks, uncertainties,
      and
      assumptions that are difficult to predict. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Readers
      are cautioned not to place reliance on these forward-looking statements, which
      speak only as of the date the statements were made. See the Company's public
      filings with the Securities and Exchange Commission for further information
      about risks and uncertainties that may affect the Company and the results or
      expectations expressed in our forward-looking statements.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Given
      these risks and uncertainties, any or all of these forward-looking statements
      may prove to be incorrect. Therefore, you should not rely on any such
      forward-looking statements. Except as required under federal securities laws,
      we
      do not intend to update publicly any forward-looking statements to reflect
      actual results or changes in other factors affecting such forward-looking
      statements.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">Page
          1</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Contact:</em></strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Advanced
      Biotherapy, Inc.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Christopher
      W. Capps - (312) 427-1912</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.advancedbiotherapy.com</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div><br>
      <div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN">
            <div style="WIDTH: 100%; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">Page
              2</font></div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0:E17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`P-CHQ,#HQ
M,R`Q-CHT-SHQ-````````Z`!``,````!``$``*`"``0````!````,J`#``0`
M```!````,0`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```5O````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`,0`R`P$B``(1`0,1`?_=``0`
M!/_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`[/Z[?6/"Z+TI[+<JW#RLMKFXEM-?J.#A
M'O\`?^BV-_PGNW[/YI<?_BY^NF75U%_0NMY!N^TOWXN2]V_](_W^GZI/NJR)
MWT_R_P#C5WOUE^K^)]8>DV]/R1!/NHM[UV`?H[6_]_\`^#7A.7@Y>-D6])S&
MFKJ."XBJ))('O]%CF_\`;^,__P!*5K3Y+'BRX)XZ]1UE?Z,O\GEA_4_SBR1(
M-OL72KLD_6G-8X.%7ZUML-DAVPX`8STO\']GWNV?\<L;'S<UGU2ZY8+;:K:\
M.BRL^H2X.?2USLAE@=^C=D.]ZL_XMNM8/6L=[[R?VUCBP9.YQ/J-M]'?DL9_
M+^S4-L_<M_XY:'7,3ZN_5OZLYWVIMEF+?6VEU;K'&RW:WTL?%KL<=S=K1_8K
M_2*+CX)^W*$N.\4>&K_FYWI_>_1377S:'U^^N)Z-T>KI^%:?VMG5-@MU=76X
M;7W?\99]"G_MS_!H/^+;ZRLMK_8W4NHVY?522YE5H+@UK1N=2S)U=8]C?YWU
M7_\`!UKS/)S\S*R']8S'>IEY)C&:1NB/T>]C?W,9H]+'_P"$_P"*7K/^+GZH
M'H73CFYK?\J9H!L!U-=?TF4_UW?3O_S/\&ILV&&#E."8]<M=/FEF[7_F\7Z2
M`296'L4DDEEKW__0]561U+ZJ=!ZIU*GJ>=BB[*QQM822`8.YGJM;'J^G^9O6
MNDC&4HZQ)CI6FFBGQ_JF*SZN?XS\1G27&BO*NH+ZQ]$-R7^GD4AO^B=^8S_!
MH_\`C0LNS_K?T[H]MI9B%M(`'#776.JMMCZ.[8U-]=O_`,J'3/\`C,+_`,^A
M1_QA`N_QC=-:.2,0#YW/6SBE>7EI2UF<!]77S8SL?-[UOU%^K#<S$S68;6WX
M(:*B"=IV#95ZM?T+'5_3W_OK?226/*<I5Q2,JVLVR4I)))-4_P#_T?54DDDE
M/DOUV_\`RG],_P",PO\`SZ$OK]_^4GI?_H)_Y^<N^ZA]3>A]1ZS5UK*98[-H
M=6ZMPL(:#4=]7Z/Z/TDW5/J9T3JO5JNKY;;3ET;/3+'EK?T;O4K]O]97X<YC
MC+$2)?J\1Q';YCV6&)(([NZDDDJ"]22222G_TO54E\JI)*?JI)?*J22GZJ27
MRJDDI^JDE\JI)*?_V?_M"U10:&]T;W-H;W`@,RXP`#A"24T$)0``````$```
M```````````````````X0DE-`^T``````!``2`````$``0!(`````0`!.$))
M300F```````.`````````````#^````X0DE-!`T```````0```!X.$))3009
M```````$````'CA"24T#\P``````"0```````````0`X0DE-!`H```````$`
M`#A"24TG$```````"@`!``````````(X0DE-`_4``````$@`+V9F``$`;&9F
M``8```````$`+V9F``$`H9F:``8```````$`,@````$`6@````8```````$`
M-0````$`+0````8```````$X0DE-`_@``````'```/__________________
M__________\#Z`````#_____________________________`^@`````____
M_________________________P/H`````/__________________________
M__\#Z```.$))300````````"``$X0DE-!`(```````0`````.$))300(````
M```0`````0```D````)``````#A"24T$'@``````!``````X0DE-!!H`````
M`ST````&```````````````Q````,@````0`;`!O`&<`;P````$`````````
M`````````````````0``````````````,@```#$`````````````````````
M`0`````````````````````````0`````0```````&YU;&P````"````!F)O
M=6YD<T]B:F,````!````````4F-T,0````0`````5&]P(&QO;F<`````````
M`$QE9G1L;VYG``````````!"=&]M;&]N9P```#$`````4F=H=&QO;F<````R
M````!G-L:6-E<U9L3',````!3V)J8P````$```````5S;&EC90```!(````'
M<VQI8V5)1&QO;F<`````````!V=R;W5P241L;VYG``````````9O<FEG:6YE
M;G5M````#$53;&EC94]R:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E
M;G5M````"D53;&EC951Y<&4`````26UG(`````9B;W5N9'-/8FIC`````0``
M`````%)C=#$````$`````%1O<"!L;VYG``````````!,969T;&]N9P``````
M````0G1O;6QO;F<````Q`````%)G:'1L;VYG````,@````-U<FQ415A4````
M`0```````&YU;&Q415A4`````0```````$US9V5415A4`````0``````!F%L
M=%1A9U1%6%0````!```````.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL
M5&5X=%1%6%0````!```````):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z
M06QI9VX````'9&5F875L=`````EV97)T06QI9VYE;G5M````#T53;&EC959E
M<G1!;&EG;@````=D969A=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI
M8V5"1T-O;&]R5'EP90````!.;VYE````"71O<$]U='-E=&QO;F<`````````
M"FQE9G1/=71S971L;VYG``````````QB;W1T;VU/=71S971L;VYG````````
M``MR:6=H=$]U='-E=&QO;F<``````#A"24T$*```````#`````$_\```````
M`#A"24T$%```````!`````(X0DE-!`P`````!8L````!````,@```#$```"8
M```=&```!6\`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT`
M`?_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3
M$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+
M#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#/_``!$(`#$`,@,!(@`"$0$#$0'_W0`$``3_Q`$_
M```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!````````
M``$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B
M<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V
M%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G
M=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1
M%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1E
MXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>G
MM\?_V@`,`P$``A$#$0`_`.S^NWUCPNB]*>RW*MP\K+:YN);37ZC@X1[_`'_H
MMC?\)[M^S^:7'_XN?KIEU=1?T+K>0;OM+]^+DO=O_2/]_I^J3[JLB=]/\O\`
MXU=[]9?J_B?6'I-O3\D03[J+>]=@'Z.UO_?_`/@UX3EX.7C9%O2<QIJZC@N(
MJB22![_18YO_`&_C/_\`2E:T^2QXLN">.O4=97^C+_)Y8?U/\XLD2#;[%TJ[
M)/UIS6.#A5^M;;#9(=L.`&,]+_!_9][MG_'+&Q\W-9]4NN6"VVJVO#HLK/J$
MN#GTM<[(98'?HW9#O>K/^+;K6#UK'>^\G]M8XL&3N<3ZC;?1WY+&?R_LU#;/
MW+?^.6AUS$^KOU;^K.=]J;99BWUMI=6ZQQLMVM]+'Q:[''<W:T?V*_TBBX^"
M?MRA+CO%'AJ_YN=Z?WOT4UU\VA]?OKB>C='JZ?A6G]K9U38+=75UN&U]W_&6
M?0I_[<_P:#_BV^LK+:_V-U+J-N7U4DN95:"X-:T;G4LR=76/8W^=]5__``=:
M\SR<_,RLA_6,QWJ9>28QFD;HC]'O8W]S&:/2Q_\`A/\`BEZS_BY^J!Z%TXYN
M:W_*F:`;`=377])E/]=WT[_\S_!J;-AA@Y3@F/7+73YI9NU_YO%^D@$F5A[%
M)))9:]__T/55D=2^JG0>J=2IZGG8HNRL<;6$D@&#N9ZK6QZOI_F;UKI(QE*.
ML28Z5IIHI\?ZIBL^KG^,_$9TEQHKRKJ"^L?1#<E_IY%(;_HG?F,_P:/_`(T+
M+L_ZW].Z/;:68A;2`!PUUUCJK;8^CNV-3?7;_P#*ATS_`(S"_P#/H4?\80+O
M\8W36CDC$`^=SULXI7EY:4M9G`?5U\V,['S>];]1?JPW,Q,UF&UM^"&BH@G:
M=@V5>K7]"QU?T]_[ZWTDECRG*5<4C*MK-LE*22235/\`_]'U5))))3Y+]=O_
M`,I_3/\`C,+_`,^A+Z_?_E)Z7_Z"?^?G+ONH?4WH?4>LU=:RF6.S:'5NK<+"
M&@U'?5^C^C])-U3ZF=$ZKU:KJ^6VTY=&STRQY:W]&[U*_;_65^'.8XRQ$B7Z
MO$<1V^8]EAB2".[NI))*@O4DDDDI_]+U5)?*J22GZJ27RJDDI^JDE\JI)*?J
MI)?*J22G_]D`.$))300A``````!3`````0$````/`$$`9`!O`&(`90`@`%``
M:`!O`'0`;P!S`&@`;P!P````$@!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H
M`&\`<``@`$,`4P````$`.$))300&```````'``@````!`0#_X1?X:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@8F5G:6X])^^[OR<@
M:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"<_/@H\>#IX;7!M971A('AM
M;&YS.G@])V%D;V)E.FYS.FUE=&$O)R!X.GAM<'1K/2=835`@=&]O;&MI="`S
M+C`M,C@L(&9R86UE=V]R:R`Q+C8G/@H\<F1F.E)$1B!X;6QN<SIR9&8])VAT
M='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,G('AM
M;&YS.FE8/2=H='1P.B\O;G,N861O8F4N8V]M+VE8+S$N,"\G/@H*(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.C`Q9&(V-S5E+35A9F,M,3%D
M8BUA,3@Y+3AD,6$W,S=B83ED9"<*("!X;6QN<SIE>&EF/2=H='1P.B\O;G,N
M861O8F4N8V]M+V5X:68O,2XP+R<^"B`@/&5X:68Z0V]L;W)3<&%C93XQ/"]E
M>&EF.D-O;&]R4W!A8V4^"B`@/&5X:68Z4&EX96Q81&EM96YS:6]N/C4P/"]E
M>&EF.E!I>&5L6$1I;65N<VEO;CX*("`\97AI9CI0:7AE;%E$:6UE;G-I;VX^
M-#D\+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@/"]R9&8Z1&5S8W)I<'1I;VX^
M"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z,#%D8C8W-64M
M-6%F8RTQ,61B+6$Q.#DM.&0Q83<S-V)A.61D)PH@('AM;&YS.G!D9CTG:'1T
M<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R<^"B`\+W)D9CI$97-C<FEP=&EO
M;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HP,61B-C<U
M92TU869C+3$Q9&(M83$X.2TX9#%A-S,W8F$Y9&0G"B`@>&UL;G,Z<&AO=&]S
M:&]P/2=H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C`O)SX*("`\
M<&AO=&]S:&]P.DAI<W1O<GD^/"]P:&]T;W-H;W`Z2&ES=&]R>3X*(#PO<F1F
M.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U
M=6ED.C`Q9&(V-S5E+35A9F,M,3%D8BUA,3@Y+3AD,6$W,S=B83ED9"<*("!X
M;6QN<SIT:69F/2=H='1P.B\O;G,N861O8F4N8V]M+W1I9F8O,2XP+R<^"B`@
M/'1I9F8Z3W)I96YT871I;VX^,3PO=&EF9CI/<FEE;G1A=&EO;CX*("`\=&EF
M9CI84F5S;VQU=&EO;CXW,B\Q/"]T:69F.EA297-O;'5T:6]N/@H@(#QT:69F
M.EE297-O;'5T:6]N/C<R+S$\+W1I9F8Z65)E<V]L=71I;VX^"B`@/'1I9F8Z
M4F5S;VQU=&EO;E5N:70^,CPO=&EF9CI297-O;'5T:6]N56YI=#X*(#PO<F1F
M.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U
M=6ED.C`Q9&(V-S5E+35A9F,M,3%D8BUA,3@Y+3AD,6$W,S=B83ED9"<*("!X
M;6QN<SIX87`])VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\G/@H@(#QX
M87`Z0W)E871E1&%T93XR,#`V+3$P+3$S5#$V.C0W.C$T+3`U.C`P/"]X87`Z
M0W)E871E1&%T93X*("`\>&%P.DUO9&EF>41A=&4^,C`P-BTQ,"TQ,U0Q-CHT
M-SHQ-"TP-3HP,#PO>&%P.DUO9&EF>41A=&4^"B`@/'AA<#I-971A9&%T841A
M=&4^,C`P-BTQ,"TQ,U0Q-CHT-SHQ-"TP-3HP,#PO>&%P.DUE=&%D871A1&%T
M93X*("`\>&%P.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO<"!#4R!7:6YD
M;W=S/"]X87`Z0W)E871O<E1O;VP^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HP,61B-C<U92TU869C
M+3$Q9&(M83$X.2TX9#%A-S,W8F$Y9&0G"B`@>&UL;G,Z>&%P34T])VAT='`Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\G/@H@(#QX87!-33I$;V-U;65N
M=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#IE,V4W86$X."TU869B+3$Q9&(M
M83$X.2TX9#%A-S,W8F$Y9&0\+WAA<$U-.D1O8W5M96YT240^"B`\+W)D9CI$
M97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I
M9#HP,61B-C<U92TU869C+3$Q9&(M83$X.2TX9#%A-S,W8F$Y9&0G"B`@>&UL
M;G,Z9&,])VAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O)SX*("`\
M9&,Z9F]R;6%T/FEM86=E+VIP96<\+V1C.F9O<FUA=#X*(#PO<F1F.D1E<V-R
M:7!T:6]N/@H*/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"CP_>'!A8VME="!E
M;F0])W<G/S[_X@Q824-#7U!23T9)3$4``0$```Q(3&EN;P(0``!M;G1R4D="
M(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@<U)'0@``````````
M````````]M8``0````#3+4A0("``````````````````````````````````
M`````````````````````````````!%C<')T```!4````#-D97-C```!A```
M`&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"&````!1G6%E:```"
M+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D```"Q````(AV=65D
M```#3````(9V:65W```#U````"1L=6UI```#^````!1M96%S```$#````"1T
M96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```"`QB5%)#```$/```
M"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L971T+5!A8VMA<F0@
M0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV-BTR+C$`````````
M`````!)S4D="($E%0S8Q.38V+3(N,0``````````````````````````````
M````````````````````````````````````6%E:(````````/-1``$````!
M%LQ865H@`````````````````````%A96B````````!OH@``./4```.06%E:
M(````````&*9``"WA0``&-I865H@````````)*````^$``"VSV1E<V,`````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````%DE%0R!H='1P
M.B\O=W=W+FEE8RYC:```````````````````````````````````````````
M``````````````````!D97-C`````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(``````````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M````````````````````9&5S8P`````````L4F5F97)E;F-E(%9I97=I;F<@
M0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````````+%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$`````````````
M`````````````````````'9I97<``````!.D_@`47RX`$,\4``/MS``$$PL`
M`UR>`````5A96B```````$P)5@!0````5Q_G;65A<P`````````!````````
M`````````````````H\````"<VEG(`````!#4E0@8W5R=@````````0`````
M!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4`%D`7@!C`&@`;0!R
M`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`Q@#+`-``U0#;`.``
MY0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%`4P!4@%9`6`!9P%N
M`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!\@'Z`@,"#`(4`AT"
M)@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,`
M`PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$
M$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)
M!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&
MP`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:
M"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*
M/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q#
M#%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.
MFPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3
M$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43
MY10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6
M%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`911EK&9$9MQG=&@0:
M*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC',P<]1T>'4<=<!V9
M'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A
M=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-)'PDJR3:)0DE."5H
M)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TI
MT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,+4$M=BVK+>$N%BY,
M+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS
M1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0
M.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]
MX#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N0C!"<D*U0O=#.D-]
M0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)
MJ4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE3FY.MT\`3TE/DT_=
M4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6
MJ5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX
M7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1`9)1D
MZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7
M;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T
M<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!
M?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"](-7@[J$'82`A..%
M1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_
MCF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7
M=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`GJZ?'9^+G_J@::#8
MH4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K
M`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+LL*S.+.NM"6TG+43
MM8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_
M]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JW
MRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.U='6
M5=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZBWRG?K^`VX+WA1.',
MXE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN
M*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7
M^N?[=_P'_)C]*?VZ_DO^W/]M____[@`.061O8F4`9$`````!_]L`A``!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("
M`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"``Q`#(#
M`1$``A$!`Q$!_]T`!``'_\0!H@````8"`P$`````````````!P@&!00)`PH"
M`0`+`0``!@,!`0$````````````&!00#!P((`0D`"@L0``(!`P0!`P,"`P,#
M`@8)=0$"`P01!1(&(0<3(@`(,11!,B,5"5%"%F$D,Q=2<8$88I$E0Z&Q\"8T
M<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D@W23A&6CL\/3XRDX
M9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9FJ2EIJ>HJ:JTM;:W
MN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$``@$#`@0$`P4$!`0&
M!@5M`0(#$00A$@4Q!@`B$T%1!S)A%'$(0H$CD152H6(6,PFQ),'10W+P%^&"
M-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58WA(6CL\/3X_,I&I2D
MM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'U^?W2%AH>(B8J+C(
MV.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#9
MC_G6_P`Q;IOX)?%C<&!WCWKVGT!W/WKM[<FW/C_OCJ3J^#LC=&%W=A1C:B?<
M1I=R4*[$_@&$EK:5,Q#45U-E9,;5R'&VK/#+'D#]WWVMYIYZYCFYEV?DRQW[
M8-B9)KVSN)UC%PKA]-O&BR+(T\JI*ULSK]+XT0%P735#(4;O=V\$`@EN7BDD
M/:RUP00:DC\(-`PK4J2*4/6N+_PG3_G1]J[/^1>X?Y?/SP[;RW8J]T;MGW1T
M%W3O#>/]]9*7LS>,+[IJ-I5N_*S(5HS>QNY:.OAR.V:D3F*'*SB"(.F4C%-E
M3][3V9Y.W[D3:/?7VNBMH=L@MH([B&W@\**6U)6""98E1#;S6ATV\\,D2%8P
M$?P7M3'*3;%N-Q%=2;9>DER202:D-Q(KFH;B"#QX5#5%\_Q6WEV-6?S1?DYA
M\M0[FI-H2/\`-HXS==9V559S'[TGV7EO@!C\!@$V')5R2[4I^H:/<E8F,F=1
M!(-QU@I%C)JC)CQSSX!^[[R=$AB9H9=IH@B1#;B=>8Y&D$@4&0W[H?%`-5-A
M$9"0\.DSM5IO%U)W597'Q$@Z3%3MK0%=7$`%M5/P]5J]?]R]TX?^4G_-2W)#
MOGM/8N[MH?#?XR[^V7/_`*4]Q9O<F%W!O3XR83-YWN7:^[Z//U=;M3*]NYN&
M3*U-'35$%725$9DJ%2>9Q[GSF;8N7Y_O`^TT1L;&]M&W;F&%S]-&L=+.^OEM
M[)X7C"RC;D6..*5E9"NA(B8X4Z*;0?3[1?B%/"_3A-%QQC1=51PU``4\@!T.
MO\^W^<14?"#X>=??&[HG>]6_S:^2W5FTXJ*NPM4]?NWJ?K//XJGQN?[+GG1I
M:^AWGO&>*JQ>VI015BL-3D(7$E"GDA_[HGLA;^Y?-TO-_--I#)R#L;AYDF(\
M.XN`I>*%T8%'A2@EN5<A&33&X9)&'1ES!N,EG#'!;/2YD/H2=-"#0@C2U:4-
M&X&@!H0'G_";K^97@]WX!_@Y\GOF/VWWI\UJVNS6>V]L;LO#Y'<^%V9MC:FW
MY\IE^O=L]S?8Y'+[LW5M?$TDD^X(=P9"-<?6P24&.$HI)I)A%]ZSD%]]OMU]
MV.0N1-ML/;6UG:UDN;18[;ZJ59UAEO!:QLL)M3=R&VAG@A4RL#(Q>%X'Z9V&
M[:,"PO+AFNS0J"2U%T@@$D5#4J2I+4%,@EE&W![P>Z$_7__0W`_YDW\O_J/^
M91\4]]_&SM2EIZ2LR$;;DZMWV*83Y7J_M7$T%=!M7>^*(TRO'3FNFI,C3*RB
MNQ574TQ*^4.LF>T7N?OOM#SSM?.6QO716*XB-=-Q;.5\6%@&6M=*O&2:+,D;
MYTTZ0;E9K?6<T!4&2E5J:`,!VYHU!Y$@'!.#U\G?M7HSMGJS?V_?AUW3@LGL
MKY5_&'<>:Q>R#239"LR^;I,/.NY).MMNY3%-']S3U-/63;KV3E(?(]<*DTE*
MS??8]8NR^U;3RON^SW_,&S7<-W[,<V6HDN+,A`D5Q?-IFO$9J-"LI94O+4,!
M#="2Y5$G-QKC]Y)XY%BD4KN,#4#9J0O!?G3\+>:T'"E-]+_A-K\SNCOG/U_G
M\]ONJR8_F`=54/95/W1+F=XUU9_I8VEW#4]*4>?[MV]MF6J6GH8-P2]*;5H,
MW#3Q"+&YVGFJ$$2YE0_+_P"\;[;>XGM)>VW*6Y[A+>>W#+;BQN!!'&CK;-?-
M;PW#QQJ#>6XO;RNIV:2.4,/TUCCA&NT7EI?J9T0+>9U"I/'34@$_"=*_81ZU
M)./\W>J?Y=?\KG^6E\J3V[ANP=T]/=I[#VSU+E]E[@[;WIG.S.X9<'M*/8G3
M71FT=XY3+5.=PF-Q&"QPI8IZ<ZL7BHJROJ6E$,KD-<I\R>]/N[[F<L_U7O!+
MSI%///"\<-O!#`\[&2]NYE2(0*LSLTMRSQL)7?0J,SQQ%Z>';K"SF\9:6Q`!
MJ22:851FN.`S@"OJ>OFU]D]Z]N]L=@;H^:W=.73>'>/<69GQ/2F'K\?/G*;#
M0X6./9]%N/;N+DGEAQVW^EL-CZ3!;1I)XY6ER\<55:9L;5"?J)R=[/[5R3[>
MP>S>Q7XBL6K+O]_&S022"2-&D2(L6*->H!`9$.FWLXYSKBNFA8@JXW"2YNSN
M$JU;A$IR!0XKZZ>-/-B.*UZ^AC_PG/\`Y0M1_+W^/=7WSWM@VC^8?R3Q&/R>
M\J3*Z*K(]1=<O4/EMN=9QU,JO4P;GRS3193=+:@3D1!1,'_APGFYW?>G][-M
M]Q=^VWDCDF&&'VTY='@6@BTB.>1%$1FC50%2WC11#:HNH>$IEU#QA%$*MDVM
MK13>7+,;Z0&M2<!B#0BM"U14L145(%,ZMD?WB=T?]?_1W^/?NO=5U_(W^5)\
M#_EG\D>L_E;W]T5AM_\`<'56&3"X#(U>2R^-PF9BH,C'E-MU>]\#AJW'T6]Z
MS9U69CB_XE]Q#3K4N&CD"0>&0=F]U?<+E_D[>.0-FYHG@Y/OR_CVP$95_$54
MD`=D,B+(J@.L;JK"NH'4U4DEC:2W$=U)"#<)2ASBG#Y&GSZTG?E#UCBOY8O_
M``IZ^/.&^'F3RW5^UN[N[/CEE-R[1QTL*;;HMN?*+LBDVAV_USC<1###1?W`
MR<-955&/QTL;PXF62#[41_94ABZ2<J[W<>]7W+><[KW!7ZW<]JV^_P##G<DS
M/-MEO]1:W#R&KF846.:2I:=?$\5F\:2H0GC&W<Q6ZVG:CNM1Y4<T84]/,#RQ
M3@.A-_X5`[AWG\@_YNWPP^%&[=^9C`]'U^V^BZ2BQU!,BT>W,]WSV]G-D;VW
MV*&ID7%UF>IL!B*-():A3XHJ8IJ".X*7[E&U6O+'LAS_`.X5C8K<<QRW%T0-
M.62RME>&`%:N0TKR,=/$N`%JH)1<R[A)-?7-LL)*VU`%!RY9%DQC!.H*!1N%
M?.@VNJ+^1E_+&Q?<7QX[VP_QKP6)["^-&.VCC-AU-%E<Q_=_-1]?[>IL!L:M
MW]M&IJZG;&[LYM5J*"OI<C-2I7MDX(ZB::5E`]X!O[^>[[6'-6U)SW>IMF]3
MRS748*G6\P"R!965IXD9%6/1'*J^&H2E":C3]S;<R0)-;+(40+5@.X`4[E`"
M&N2>VE2<4H.K;_<0=&?7O?NO=?_2W^/?NO=>]^Z]U\\G^=B[1_\`"GOX,.I(
M8=D_R[`"I*D%N^L>MP1R"+^^G7LC<-;?<@]UY%K4Q[NF#3$EM%&?RHQJ/,8\
M^@9N0U<R6(^<?\B3TV_\*#:2;)?\*+?A7C(&C2:NQ?P?I(7E9EA6:L^0V[J=
M&D*)(RQJQ!8A6-OP?9A]RO<ULO83W<DF5C;VMY=S$`U)'[NA+!5-!JI$,U%<
M`TI7I-S7(MO>6]RX)5(JFG&BLQQ_DZ^B1[Y:]#SKWOW7NO>_=>Z__]/?X]^Z
M]U[W[KW7SR/YV8O_`,*>O@R!_P`_)_EV'_DGOO',?]X'OIO[*Q--]Q[W612*
MA=U;/HEO$Q_.@-/GT#-Q-.9;'_:?X3UR_GY#_MI'^"K?@CX'C_;?)'=)/_0W
MO7W0(F7[N?OE.2-#-?*/6J[8A/Y=XI^?1?SN<D?\NS?\_=?0U]\R>I#Z][]U
M[KWOW7NO_]3?X]^Z]U[W[KW56'?W\F_X1?)?YC[#^=G:VV>PLI\@NM\UU7N#
M:>5QW9>Y,5M>AR/36;I-P[&9MITTW\+DIJ3+422U$-A%5,6\BDNY:2]G]X?<
M?8.3-P]OMGYE:#DZ[CE2:V6&WTR+.")=3F(RZG#:2WB:@H500J*`CDV^SEN$
MNY(:W"D$&IQ3ABM/Y=1/E'_)F^%'S`^6'7WS1[DQ/9U1WCUDG7$>U,EMCLC+
M;;P%*.J]T5>[]HM-@Z.!XY)*?-ULCS,LB&52!P>?=>4_=_W&Y&Y>WCE3E7F9
M[3E[<&D-Q"(H'$AEB$,E6EB=QJC4(=++@5%#GJMUMMC>N'N[99&`IFM*>A%:
M$9X$9ZM:]QMTNZ][]U[KWOW7NO_5W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
)[KW7O?NO=?_9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
